HTA150 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany: Update Until Mai 2024
Abstract
Authors
S Brückel S Reindl